Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Astrazeneca (AZNCF) over the last 15 years, with Q4 2025 value amounting to $1.5 billion.

  • Astrazeneca's Depreciation & Amortization (CF) fell 3534.45% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.7 billion, marking a year-over-year decrease of 1427.93%. This contributed to the annual value of $5.7 billion for FY2025, which is 1427.93% down from last year.
  • Latest data reveals that Astrazeneca reported Depreciation & Amortization (CF) of $1.5 billion as of Q4 2025, which was down 3534.45% from $1.5 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Depreciation & Amortization (CF) registered a high of $2.8 billion during Q3 2021, and its lowest value of $753.0 million during Q2 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.4 billion (2022), whereas its average is $1.5 billion.
  • In the last 5 years, Astrazeneca's Depreciation & Amortization (CF) skyrocketed by 8021.25% in 2022 and then plummeted by 3534.45% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's Depreciation & Amortization (CF) stood at $2.2 billion in 2021, then plummeted by 38.09% to $1.4 billion in 2022, then dropped by 5.97% to $1.3 billion in 2023, then surged by 83.15% to $2.3 billion in 2024, then plummeted by 35.34% to $1.5 billion in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.5 billion for Q4 2025, versus $1.5 billion for Q3 2025 and $1.4 billion for Q2 2025.